Clinical trials: Malignant Solid Tumours
Liver Cell Carcinoma, Solid Tumor
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor
- Trial name
- NCT05103631
- Testing
- CATCH T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Advanced Solid Tumors
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Study Population: Adult subjects aged 18-75 years with relapsed/refractory advanced solid tumors (including liver, gastric, colorectal, ovarian cancer, etc.) and malignant ascites confirmed by cytology, who have failed at least 2…
- Trial name
- NCT07561437
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Malignant Solid Tumor
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors
An open-label, single-arm, single-dose escalation and multiple-dose expansion clinical study of cell therapy to observe and to evaluate the tolerance, the pharmacokinetic characteristics, the safety, and the efficacy of ScTIL210…
- Trial name
- NCT04571892
- Testing
- Super circulating tumor infiltrating lymphocytes(ScTIL)
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Shanghai East Hospital
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg
Advanced Malignant Solid Tumor
Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies.
- Trial name
- NCT04758897
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Collection of Outcomes Data for Pregnant Patients With Cancer
This study collects treatment and outcomes information on pregnant patients who are or were pregnant with cancer. Gathering and storing health information on pregnant patients with cancer, may provide data for future research…
- Trial name
- NCT00507572
- Testing
- Medical Chart Review
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Study of Attention and Memory Treatments for Cancer Survivors
This clinical trial investigates if certain electronic games may be effective in improving attention and memory function in cancer survivors.
- Trial name
- NCT04870320
- Testing
- Endeavor: Computer-Based Cognitive Stimulation Intervention, Words!: Computer-Based Cognitive Stimulation Intervention, Quality of Life (QOL) Questionnaires
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Mesothelin-positive Advanced Malignant Solid Tumors
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid…
- Trial name
- NCT07010523
- Testing
- Anti-mesothelin CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory).
- Trial name
- NCT03253679
- Testing
- Adavosertib
- Where
- 9 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.
- Trial name
- NCT05496972
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphocytes
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors.
- Trial name
- NCT06047977
- Testing
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Malignant Solid Tumors
A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients
This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy to observe and evaluate the safety and efficacy of T60c injection in the treatment of patients with advanced…
- Trial name
- NCT06082557
- Testing
- T60c injection
- Volunteers
- 62 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Malignant Solid Tumor, Hematologic Malignancies
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
The primary objective of this study is to establish the feasibility and value of physical fitness assessment within patients receiving cytotoxic chemotherapy.
- Trial name
- NCT02844400
- Testing
- Biometric Devices, Physical Performance Testing
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Cancer
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts.
- Trial name
- NCT02317419
- Testing
- RO6927005, gemcitabine, nab-paclitaxel
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Malignant Solid Tumour
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, dose-escalation trial in patients with advanced solid tumors. The trial comprises 2 stages: a dose escalation stage at 8 dose levels of 2, 5, 10, 20, 40, 60, 80, and 100 mg/day,and possibly…
- Trial name
- NCT01184807
- Testing
- OPB-51602
- Where
- 2 sites in Singapore
- Volunteers
- 51 people
- Sponsor
- Otsuka Beijing Research Institute
HER2-Positive Solid Tumors
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
This is a non-randomized, open-label, single-arm, multicenter Phase I clinical trial which will evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody in…
- Trial name
- NCT04280341
- Testing
- RC48-ADC in combinaton with JS001
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Testing the Safety of CB-5339 in Patients With Cancer
This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04372641
- Testing
- p97 Inhibitor CB-5339 Tosylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
This phase II trial studies how well pembrolizumab works before surgery in treating patients with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes (locally advanced).
- Trial name
- NCT04082572
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.